Big Pharma Has Eye On Pharmacopeia’s DARA For Blood Pressure
This article was originally published in The Pink Sheet Daily
Executive Summary
DARA, a first-in-class dual-acting angiotensin and endothelin receptor antagonist in development for hypertension and diabetic nephropathy, is in Phase II development.
You may also be interested in...
Wooing Partners, Pharmacopeia Shifts DARA To Kidney Disease
Cash-light firm’s move away from the crowded hypertension space could clinch a deal.
Wooing Partners, Pharmacopeia Shifts DARA To Kidney Disease
Cash-light firm’s move away from the crowded hypertension space could clinch a deal.
Pharmacopeia Targets 2009 For SARM Phase II After Gaining Program From Bristol
Company licenses the Phase I selective androgen receptor modulator for muscle wasting from Bristol in exchange for research support.